High Level Expression Of A Functional Humanized Single-chain Variable Fragment (scFv) Antibody Against CD22 Marker In Pichia Pastoris | 49596
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand
Google scholar citation report
Citations : 1536

Journal of Biotechnology & Biomaterials received 1536 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

High level expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 marker in Pichia pastoris

11th World Congress on Biotechnology and Biotech Industries Meet

Najmeh Zarei

Pasteur Institute of Iran, Iran

Posters & Accepted Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.053

ScFvs have recently emerged as attractive candidates in targeted immunotherapy of various malignancies. The anti-CD22 scFv is able to target CD22, on B-cell surface and is being considered as a promising molecule in targeted immunotherapy of B-cell malignancies. The recombinant anti-CD22 scFv has been successfully expressed in Escherichia coli; however, the insufficient production yield has been a major bottleneck for its therapeutic application. Pichia pastoris has become a highly popular expression host for the production of antibody fragments. In this study we used the Pichia expression system to express a model scFv against CD22. The full-length humanized scFv gene was introduced into the expression vector pPICZ╬▒A under the control of the AOX1 promoter and expressed in GS115 strain. The maximum production level of the scFv were achieved at methanol concentration, 1%; pH, 6.0; inoculums density, OD600=3 and the induction time of 72 hours. Using affinity chromatography, 72% of the recombinant protein was recovered with a purity and final yield of about 93% and 25 mg/L, respectively. The correlation between scFv gene dosage and expression level was also investigated by real time PCR and the results confirmed the presence of such correlation up to 5 gene copies. Flowcytometry and biacore analysis demonstrated binding to CD22 on the surface of human lymphoid cell line Raji and recombinant CD22, respectively. Taken together, the presented data suggest that the Pichia pastoris can be considered as an efficient host for the large-scale production of anti-CD22 scFv as a possible promising carrier for targeted drug delivery.

Najmeh Zarei has completed her PharmD degree and PhD in the field of Pharmaceutical Biotechnology from Pasteur Institute of Iran. She is currently working as an Assistant Professor of the Pasteur Institute of Iran and has published more than 10 papers in reputed journals.

Email: [email protected]